COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 85 of 361 for:    ASPIRIN AND clopidogrel AND Purinergic Antagonists

Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes (TC4)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04057300
Recruitment Status : Recruiting
First Posted : August 15, 2019
Last Update Posted : September 2, 2020
Canadian Institutes of Health Research (CIHR)
Information provided by (Responsible Party):
James Brophy, McGill University Health Centre/Research Institute of the McGill University Health Centre

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 31, 2021
Estimated Study Completion Date : March 31, 2021
Center for Drug Evaluation and Research. Complete Response Review Addendum Sponsor Safety Reporting Submissions: NDA 22-433 and IND 65,808 SD 632 Drug: ticagrelor (BrilintaTM). 2011. https://wwwaccessdatafdagov/drugsatfda_docs/nda/2011/022433Orig1s000MedRpdf.